SNSE Sensei Biotherapeutics

Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference

Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in Citi’s 2024 Global Healthcare Conference, being held on December 3-5, in Miami, FL.

About Sensei Biotherapeutics  

Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead product candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visit , and follow the company on X @SenseiBio and .

Investor Contact:

Michael Biega

Senior Director, Investor Relations

Sensei Biotherapeutics

Media Contact:

Joyce Allaire

LifeSci Advisors



EN
27/11/2024

Underlying

SNSESensei Biotherapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sensei Biotherapeutics

 PRESS RELEASE
Free
SNSE Sensei Biothera...

Sensei Biotherapeutics Announces Initiation of Strategic Review to Max...

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value BOSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that its Board of Directors has determined, after extensive consideration of the Company’s development pipeline and current market conditions, to discontinue development of solnerstotug and initiate a comprehensive review of strategic alternatives aimed at maximizi...

13h / 7m 1 EN
 PRESS RELEASE
Free
SNSE Sensei Biothera...

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durab...

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025 6-month progression-free survival (PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings –All clinical responses, including a complete response, observed in the higher 15 mg/kg dose cohort –Favorable safety profile with six cases of mild, manageable grade 1 cytokine release syndrome (CRS) across all patients treated to date, all of which occurred in the 15 mg/kg dos...

October 17, 2025 1 EN
 PRESS RELEASE
Free
SNSE Sensei Biothera...

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose ...

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025 BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will host a virtual key opinion leader (KOL) event on Monday, October 20, 2025 at 8:00 AM ET featuring company leadership and Kyriakos Papadopoulos, MD (Co-Director of Clinical Research at START, San ...

September 23, 2025 1 EN
 PRESS RELEASE
Free
SNSE Sensei Biothera...

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annu...

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in 1x1 investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025. An on-demand corporate presentation will be available on Sept...

September 3, 2025 1 EN
 PRESS RELEASE
Free
SNSE Sensei Biothera...

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results a...

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter 2025, and provided a corporate update. “The second quarter was ...

August 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch